Macquarie Group’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Macquarie Group’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-63	Closed	-$6K	–	2397
2020 Q2	$6K	Buy	+63	New	+$6.74K	﹤0.01%	2339
2019 Q2	–	Sell	-60,756	Closed	-$5.54M	–	1915
2019 Q1	$5.54M	Sell	60,756 -50,400	-45%	-$4.12M	0.01%	751
2018 Q4	$8.44M	Sell	111,156 -1,800	-2%	-$132K	0.02%	632
2018 Q3	$9.04M	Sell	112,956 -229,298	-67%	-$21.4M	0.01%	670
2018 Q2	$34M	Sell	342,254 -242,833	-42%	-$21M	0.06%	355
2018 Q1	$47.4M	Sell	585,087 -15,600	-3%	-$1.26M	0.09%	233
2017 Q4	$41.9M	Sell	600,687 -400	-0.1%	-$33.3K	0.07%	264
2017 Q3	$55.5M	Buy	601,087 +13,500	+2%	+$1.3M	0.1%	183
2017 Q2	$66.5M	Buy	587,587 +314,700	+115%	+$35.2M	0.12%	142
2017 Q1	$27.3M	Buy	+272,887	New	+$29.2M	0.05%	371
2016 Q3	–	Sell	-51,180	Closed	-$5.44M	–	1607
2016 Q2	$5.44M	Buy	+51,180	New	+$5.94M	0.01%	855

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Macquarie Group's CBPO Position: Q3 2020 in Review

Macquarie Group sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2020, closing a stake of 63 shares — an estimated $6K sold.

Macquarie Group first reported a position in CBPO in Q2 2016 and held it in 11 quarters. The position peaked at $66.5M in Q2 2017. 87 funds tracked by Wall St. Rank hold CBPO as of Q3 2020.

Macquarie Group reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2020 after selling out during the quarter.
Macquarie Group sold 63 China Biologic Products Holdings, Inc. shares in Q3 2020, an estimated $6K.
Macquarie Group first reported a position in China Biologic Products Holdings, Inc. in Q2 2016 and held it in 11 quarters.
Macquarie Group's China Biologic Products Holdings, Inc. position peaked at $66.5M in Q2 2017.
87 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2020.

Based on Macquarie Group's 13F filing for Q3 2020, filed 13 Nov 2020.